InflaRx N.V.

Healthcare · Biotechnology · Germany

Last price 1.715 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 252.74M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its u...